Abiopharma

🔍 Grahmann Kevin P (Executive)

Company: KINDER MORGAN, INC. (KMI)

Report Date: 2026-07-31

Detailed Transactions and Holdings:

• Acquired 40,510 shares of Class P Common Stock (Direct)
  Date: 2026-07-31 | Code: M | equity_swap_involved: 0 | shares_owned_after: 99,163.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 13,576 shares of Class P Common Stock at $32.18 per share (Direct)
  Date: 2026-07-31 | Code: F | equity_swap_involved: 0 | shares_owned_after: 85,587.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 40,510 shares of Restricted Stock Unit (Derivative)
  Date: 2026-07-31 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4, F5, F5

Footnotes:

• F1: This transaction represents the settlement of restricted stock units in shares of Class P Common Stock on their scheduled vesting date.
• F2: Represents shares withheld by the issuer to satisfy tax withholding obligations upon the reported vesting of restricted stock units.
• F3: Closing price of Class P Common Stock on the date of vesting.
• F4: Each restricted stock unit represents the right to receive, at settlement, one share of Class P Common Stock.
• F5: These restricted stock units vested on July 31, 2026.